Related Experiment Videos
Roxithromycin--a new macrolide derivative.
M Hejzlar1, F Novotný, L Stastná
1Medical Faculty of Hygiene, Charles University, Prague, Czechoslovakia.
Journal of Hygiene, Epidemiology, Microbiology, and Immunology
|January 1, 1989
Summary
Roxithromycin, an oral antimicrobial, shows good efficacy against various bacteria and parasites. It is well-tolerated and effective in treating mild to moderate infections, making it suitable for pediatric use.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Roxithromycin is a derivative of erythromycin A, an oral antimicrobial.
- It exhibits activity against a range of bacteria, including staphylococci, streptococci, pneumococci, and chlamydiae.
- Higher concentrations are required for activity against enterococci and some strains of H. influenzae.
Purpose of the Study:
- To evaluate the efficacy and pharmacokinetic profile of roxithromycin.
- To determine its spectrum of activity against various pathogens.
- To assess its therapeutic effects in patients with infections.
Main Methods:
- In vitro susceptibility testing to determine minimum inhibitory concentrations (MICs).
- Pharmacokinetic studies to assess serum half-life and concentration.
- Clinical evaluation of therapeutic effects in patients with infections.
Main Results:
- Roxithromycin is active against staphylococci, streptococci, pneumococci, branhnamella, chlamydiae, campylobacters, anaerobic bacteria, Toxoplasma gondii, Treponema pallidum, Mycoplasma pneumoniae, and Legionella pneumophilla.
- Serum half-life ranges from 9 to 16 hours, with excellent tissue distribution.
- 86% of patients treated for various infections achieved bacteriological negativity.
Conclusions:
- Roxithromycin is an effective oral antimicrobial with a broad spectrum of activity.
- Its favorable pharmacokinetic profile and excellent tolerance make it suitable for treating mild to moderate infections, particularly in pediatric practice.